EFFICACY OF VEDOLIZUMAB IN REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE

被引：2
|
作者：
Tse, Chung Sang
Loftus, Edward V.
Raffals, Laura H.
Gossard, Andrea
Lightner, Amy L.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)31580-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1945
引用
下载
收藏
页码：S402 / S403
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease
    Eksteen, Bertus
    Heatherington, Joan
    Oshiomogho, John I.
    Panaccione, Remo
    Kaplan, Gilaad
    Ghosh, Subrata
    GASTROENTEROLOGY, 2016, 150 (04) : S1268 - S1268
  • [2] RETRACTED: EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE (Retracted Article)
    Eksteen, B.
    Heatherington, J.
    Oshiomogo, J.
    Panaccione, R.
    Kaplan, G.
    Ghosh, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S199 - S199
  • [3] EFFECT OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB ON BILIARY INFLAMMATION IN INDIVIDUALS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
    Tse, Chung Sang
    Raffals, Laura H.
    Loftus, Edward V.
    Gossard, Andrea
    Lightner, Amy L.
    GASTROENTEROLOGY, 2018, 154 (06) : S302 - S303
  • [4] Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
    Tse, C. S.
    Loftus, E. V., Jr.
    Raffals, L. E.
    Gossard, A. A.
    Lightner, A. L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (02) : 190 - 195
  • [5] RETRACTION: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Retraction of Vol 64, Pg S 199, 2016)
    Eksteen, B.
    Heatherington, J.
    Oshiomogo, J.
    Panaccione, R.
    Kaplan, G.
    Ghosh, S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : 254 - 254
  • [6] INTERNATIONAL EXPERIENCE OF VEDOLIZUMAB IN PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
    Williamson, Kate D.
    Lytvyak, Ellina
    de Krijger, Manon
    Trivedi, Palak
    Estes, Derek
    Yu, Le
    Pratt, Daniel
    de Vries, Annemarie C.
    Daretti, Luigi
    Liu, Chung Heng
    Bowlus, Christopher L.
    Marschall, Hanns-Ulrich
    Montano-Loza, Aldo J.
    Chapman, Roger W.
    Van der Woude, Christien Janneke
    Marzioni, Marco
    Keshav, Satish
    Ponsioen, Cyriel
    Hirschfield, Gideon
    Levy, Cynthia
    GASTROENTEROLOGY, 2018, 154 (06) : S1097 - S1097
  • [7] THE IMPACT OF PRIMARY SCLEROSING CHOLANGITIS (PSC) ON FECAL CALPROTECTIN ASSESSMENT IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE (IBD)
    Arar, Amr
    Scott, Frank I.
    Click, Benjamin
    Fennimore, Blair
    Ahmed, Waseem
    Oonk, Alexis
    Gerich, Mark E.
    GASTROENTEROLOGY, 2023, 164 (06) : S895 - S896
  • [8] The impact of Primary Sclerosing Cholangitis (PSC) on fecal calprotectin assessment in individuals with Inflammatory Bowel Disease (IBD)
    Arar, A.
    Scott, F.
    Click, B.
    Fennimore, B.
    Ahmed, W.
    Oonk, A.
    Gerich, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I400 - I402
  • [9] Effectiveness of Vedolizumab in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis
    Santiago, Priscila
    Robateau, Anthony
    Lopdrup, Rachel G.
    Neto, Manuel B. Braga
    Raffals, Laura
    Eaton, John
    Ramos, Guilherme
    Loftus, Edward V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S688 - S689
  • [10] Screening primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD)
    Farkkila, M
    Karvonen, AL
    Pikkarainen, P
    Nurmi, H
    Nuutinen, H
    Karkkainen, P
    Mattila, J
    Taavitsainen, M
    Miettinen, A
    GUT, 1997, 41 : A178 - A178
12345